Notice of extraordinary general meeting
Filed with HKEX · Stock code 2496 · · 3 pages · English
Summary by 6ix AI
Wuhan Yzy Biopharma Co., Ltd. has issued a notice for an extraordinary general meeting to be held in Wuhan, China. The meeting will consider special resolutions related to a share subscription agreement and other corporate matters. Shareholders are advised on the procedures for attending and voting at the meeting, including proxy appointment details. The notice includes information on the authorization of directors to implement the resolutions if approved.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Wuhan YZY Biopharma Co., Ltd. on 6ix
Earlier from Wuhan YZY Biopharma
- (1) Connected transaction in respect of the proposed issue of new domestic shares under Specific mandate; (2) application for Whitewash Waiver; (3) proposed amendments to the articles of association; and (4) notice of EGM
- Closure of register of members for extraordinary general meeting
- Voluntary announcement the first patient dosed in phase i clinical trial of Y225 for treatment of hemophilia a
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Delay in despatch of circular in relation to (1) connected transaction in respect of the proposed issue of new domestic shares under Specific mandate; (2) application for Whitewash Waiver; and (3) proposed amendments to the articles of association
Later from Wuhan YZY Biopharma
- Form of proxy for the extraordinary general meeting to be held on Tuesday, 17 November 2026
- Documents on Display
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Wuhan YZY Biopharma into a list and get an email when it puts out news.
Follow Wuhan YZY Biopharma